Edge Therapeutics' Series B - III Round

Edge Therapeutics raised a round of funding on June 04, 2013. Investors include Maxim Group.

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the manag…

Articles about Edge Therapeutics' Series B - III Round: